Forbes Lindsay M, Bauer Natalie, Bhadra Aritra, Bogaard Harm J, Choudhary Gaurav, Goss Kara N, Gräf Stefan, Heresi Gustavo A, Hopper Rachel K, Jose Arun, Kim Yunhye, Klouda Timothy, Lahm Tim, Lawrie Allan, Leary Peter J, Leopold Jane A, Oliveira Suellen D, Prisco Sasha Z, Rafikov Ruslan, Rhodes Christopher J, Stewart Duncan J, Vanderpool Rebecca R, Yuan Ke, Zimmer Alexsandra, Hemnes Anna R, de Jesus Perez Vinicio A, Wilkins Martin R
Division of Pulmonary Sciences and Critical Care Medicine University of Colorado Aurora Colorado USA.
Department of Pharmacology College of Medicine, University of South Alabama Mobile Alabama USA.
Pulm Circ. 2025 Jan 2;15(1):e70027. doi: 10.1002/pul2.70027. eCollection 2025 Jan.
Pulmonary vascular disease is not a single condition; rather it can accompany a variety of pathologies that impact the pulmonary vasculature. Applying precision medicine strategies to better phenotype, diagnose, monitor, and treat pulmonary vascular disease is increasingly possible with the growing accessibility of powerful clinical and research tools. Nevertheless, challenges exist in implementing these tools to optimal effect. The 2023 Grover Conference Series reviewed the research landscape to summarize the current state of the art and provide a better understanding of the application of precision medicine to managing pulmonary vascular disease. In particular, the following aspects were discussed: (1) Clinical phenotypes, (2) genetics, (3) epigenetics, (4) biomarker discovery, (5) application of precision biology to clinical trials, (6) the right ventricle (RV), and (7) integrating precision medicine to clinical care. The present review summarizes the content of these discussions and the prospects for the future.
肺血管疾病并非单一病症；相反，它可伴随多种影响肺血管系统的病理状况。随着强大的临床和研究工具越来越容易获取，应用精准医学策略来更好地表型分析、诊断、监测和治疗肺血管疾病变得越来越可行。然而，要将这些工具发挥出最佳效果仍存在挑战。2023年格罗弗会议系列回顾了研究现状，以总结当前的技术水平，并更好地理解精准医学在管理肺血管疾病中的应用。具体讨论了以下几个方面：（1）临床表型，（2）遗传学，（3）表观遗传学，（4）生物标志物发现，（5）精准生物学在临床试验中的应用，（6）右心室，以及（7）将精准医学融入临床护理。本综述总结了这些讨论的内容以及未来的前景。
